Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Zai Lab

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

Expert Ratings for Zai Lab

Expert Ratings for Zai Lab

Analysts have provided the following ratings for Zai Lab (NASDAQ:ZLAB) within the last quarter:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Zai Lab: Q1 Earnings Insights

Zai Lab (NASDAQ:ZLAB) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Zai Lab beat estimated earnings by 28.33%, reporting an EPS of $-0.86 versus an estimate of $-1.2.

Zai Lab's Earnings Outlook

Zai Lab (NASDAQ:ZLAB) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Zai Lab will report an earnings per share (EPS) of $-1.20.

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting stage, the framework from the China Securities Regulatory Commission and other national agencies would let most Chinese firms keep their U.S.…

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ:

inkl

Read news from The Economist, FT, and more,
with one subscription

Zai Lab Revenue Triples, As It Struggles To Break Cycle Of Mounting Losses

Zai Lab Revenue Triples, As It Struggles To Break Cycle Of Mounting Losses

Key takeaways: Zai Lab reported its revenue grew 194% last year, but its loss also increased by 162% as it spent heavily on R&D and marketing The company hopes heavy R&D spending can reduce its dependence on licensed products by improving its capacity to innovate By Ken Lo

Recap: Zai Lab FY Earnings

Recap: Zai Lab FY Earnings

Zai Lab (NASDAQ:ZLAB) reported its FY earnings results on Tuesday, March 1, 2022 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Zai Lab missed estimated earnings by 35.76%, reporting an EPS of $-2.24 versus an estimate of $-1.65.

A Preview Of Zai Lab's Earnings

A Preview Of Zai Lab's Earnings

Zai Lab (NASDAQ:ZLAB) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that Zai Lab will report an earnings per share (EPS) of $-1.65.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Vertex Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Pain Management

Places

322,975 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play